KDR and triple-negative breast carcinoma: In summary, TTAC-0001, a novel fully human monoclonal antibody against VEGFR-2/KDR, was shown to have anti-angiogenic effects and good anti-tumor efficacy for inhibition of tumor growth and neovascularization in a mouse orthotopic triple-negative breast cancer model.